Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy. In the past
ALL was intractable but now the survival probability is as high as 80–90%. Improved …

Identification of biologically distinctive subsets of ALL through cytogenetic, molecular, and
gene expression studies, as well as investigations of minimal residual disease and host …

Clinical trials have advanced the cure rate of childhood acute lymphoblastic leukaemia to
near 80%. Treatment response, as measured by minimal residual disease, has allowed us …

Childhood acute lymphoblastic leukemia (ALL) is the most common malignancy of
childhood. Studies in ALL have been a model for clinical and basic research beyond …

Purpose To review the impact of collaborative studies on advances in the biology and
treatment of acute lymphoblastic leukemia (ALL) in children and adolescents. Methods A …

The outcomes of pediatric acute lymphoblastic leukemia (ALL) have improved remarkably
during the last five decades. Such improvements were made possible by the incorporation of …

Improved supportive care, more precise risk stratification, and personalized chemotherapy
based on the characteristics of leukemic cells and hosts (eg, pharmacokinetics and …

The last decade has witnessed great advances in our understanding of the genetic and
biological basis of childhood acute lymphoblastic leukemia (ALL), the development of …

Advancement in the diagnosis and treatment of pedi-atric acute lymphoblastic leukemia
(ALL) is one of the greatest successes of modern medicine. Over the past 50 years, there …

Acute Lymphoblastic Leukemia in Children | New England Journal of Medicine Skip to main
content The New England Journal of Medicine homepage Advanced Search SEARCH …